NCT05957380
Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients
Dong-A ST Co., Ltd.·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Hepatitis B
- Drug/Device/Intervention
- DA-2803
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Dong-A ST Co., Ltd.
- Location
- Seoul, South Korea
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Mar 20, 2023
- End date
- Nov 30, 2024
- Enrollment
- 108 participants
Primary outcome
HBV DNA(log10 IU/mL) change
Summary
This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical
 study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects
ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05957380
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05957380 through Pure Global AI's free database. This Phase 4 trial is sponsored by Dong-A ST Co., Ltd. and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 108 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.